title: (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy.
abstract: The (90)Y and (177)Lu complexes (RP697 and RP688, respectively) of a DOTA-conjugated vitronectin receptor antagonist (SU015: 2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl)acetyl-Glu(cyclo[Lys-Arg-Gly-Asp-D-Phe])-cyclo[Lys-Arg-Gly-Asp-D-Phe]) were prepared by reacting SU015 with the radiometal chloride in ammonium acetate buffer (pH > 7.2) in the presence of an antioxidant (sodium gentisate, GA). Through a series of radiolabeling experiments, it was found that there are many factors influencing the rate of (90)Y chelation and the radiolabeling efficiency of SU015. These include the purity of SU015, the pH, reaction temperature, and heating time, as well as the presence of trace metal contaminants, such as Ca(2+), Fe(3+), and Zn(2+). The chelation of (90)Y by SU015 is slow, so that heating at elevated temperatures (50-100 degrees C) is needed to complete the (90)Y-labeling. The rate of (90)Y chelation is also dependent on the pH of the reaction mixture. Under optimized radiolabeling conditions (pH 7.2-7.8 and heating at 50-100 degrees C for 5-10 min), the minimum amount of SU015 required to achieve 95% RCP for RP697 is approximately 25 microg for 20 mCi of (90)YCl(3) corresponding to a SU015:(90)Y ratio of approximately 30:1.
authors.affiliation: Medical Imaging Division, DuPont Pharmaceuticals Company, 331 Treble Cove Road, North Billerica, Massachusetts 01862, USA. shuang.liu@dupontpharma.com
authors.forename: S
authors.initials: S
authors.lastname: Liu
authors.forename: E
authors.initials: E
authors.lastname: Cheung
authors.forename: M C
authors.initials: MC
authors.lastname: Ziegler
authors.forename: M
authors.initials: M
authors.lastname: Rajopadhye
authors.forename: D S
authors.initials: DS
authors.lastname: Edwards
mesh_terms: D002614:Chelating Agents / Q000737:chemistry; D005841:Gentisates / Q000737:chemistry; D006361:Heating; D006573:Heterocyclic Compounds, 1-Ring / Q000138:chemical synthesis / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D008187:Lutetium / Q000737:chemistry*; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry*; D011868:Radioisotopes / Q000737:chemistry*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors; D013696:Temperature; D015021:Yttrium Radioisotopes / Q000737:chemistry*
chemical_list: D002614:Chelating Agents; D005841:Gentisates; D006573:Heterocyclic Compounds, 1-Ring; D009842:Oligopeptides; D010456:Peptides, Cyclic; C436392:RP 697; C436393:RP688; D011868:Radioisotopes; D019030:Receptors, Vitronectin; D015021:Yttrium Radioisotopes; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D008187:Lutetium